How is the transformation of Bigpharma's CSPC Group?

Event: Recently, CSPC (01093.

01 Products in two major fields contribute stable cash cows

From the perspective of business segments, the proprietary medicine segment maintained steady growth and remained the largest cash cow.

Source: Company announcement

Pharmaceutical products include neurological diseases, anti-tumor, anti-infection, cardiovascular diseases, respiratory system, digestion and metabolism, and other fields

Enbipu is a Class 1 new drug developed by CSPC.

Source: Zhongkang FIC Intelligence database

02 "Creation + imitation" dual engine accelerates to seize the market

In recent years, CSPC has continuously increased R&D investment, focusing on R&D and innovation

Source: company announcement, compiled by the Zhongkang innovative drug database team

According to the announcement, the R&D progress achieved since the beginning of the year includes: Amflix’s listing in May, Crepitor’s listing application or CDE priority review, 24 and 5 research projects that have obtained clinical approvals from China and the United States respectively, and 2 projects Or FDA’s breakthrough therapy certification; 13 generic drugs have obtained Chinese drug registration approvals, 2 generic drugs have obtained American ANDA approvals, and 25 varieties (42 specifications) have passed/deemed consistency evaluation

03 Introduction + internal research and development to improve the product pipeline

CSPC introduced the respiratory system twice during the year

The six strategic cooperations carried out by CSPC this year not only fully reflect the recognition of CSPC's R&D strength by domestic and foreign pharmaceutical companies, but also prove CSPC's determination to expand its field layout

According to the FIC Intelligence database of Zhongkang, the popular Claudin 18.

Source: Zhongkang FIC Intelligence database

04 Conclusion

Different from the "big swords" wielded by other traditional pharmaceutical companies, CSPC continues to focus on the generic drug business with more than 80% of prescriptions, and at the same time accelerates R&D investment in the innovative drug sector, introduces a dual model of plus self-research, and comprehensively deploys in multiple disease areas.